Gastroenterology
Volume 138, Issue 5 , Pages 1885-1897.e10 , May 2010

Interferon-α–Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection

  • Kerstin A. Stegmann

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Niklas K. Björkström

      Affiliations

    • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Heike Veber

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Sandra Ciesek

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • Department of Experimental Virology, Twincore, Hannover, a joint venture between Hannover and the Helmholtz Centre for Infection Research, Braunschweig, Germany
    • ,
  • Peggy Riese

      Affiliations

    • Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
    • ,
  • Johannes Wiegand

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Johannes Hadem

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Pothakamuri V. Suneetha

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Jerzy Jaroszewicz

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Chun Wang

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Verena Schlaphoff

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Paraskevi Fytili

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Markus Cornberg

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Michael P. Manns

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • Robert Geffers

      Affiliations

    • Division of Cell Biology and Immune Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany
    • ,
  • Thomas Pietschmann

      Affiliations

    • Department of Experimental Virology, Twincore, Hannover, a joint venture between Hannover and the Helmholtz Centre for Infection Research, Braunschweig, Germany
    • ,
  • Carlos A. Guzmán

      Affiliations

    • Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
    • ,
  • Hans–Gustaf Ljunggren

      Affiliations

    • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Heiner Wedemeyer

      Affiliations

    • Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    • Corresponding Author InformationReprint requests Address requests for reprints to: Professor Dr Heiner Wedemeyer, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. fax: (49) 511-532-6820

Received 22 April 2009 ,Accepted 22 January 2010.

References 

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567
  2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21–S29
  3. Wiegand J, Deterding K, Cornberg M, et al. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother. 2008;62:860–865
  4. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–1754
  5. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002;169:3447–3458
  6. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195:35–41
  7. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359
  8. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351–1358
  9. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–244
  10. Lanier LL. The origin and functions of natural killer cells. Clin Immunol. 2000;95:S14–S18
  11. Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol. 1998;28:84–90
  12. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42:501–510
  13. Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies?. Liver Transpl. 2006;12:363–372
  14. Nattermann J, Feldmann G, Ahlenstiel G, et al. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut. 2006;55:869–877
  15. Yoon JC, Shiina M, Ahlenstiel G, et al. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology. 2009;49:12–21
  16. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol. 2001;31:3138–3146
  17. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–256
  18. Pfoertner S, Jeron A, Probst-Kepper M, et al. Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol. 2006;7:R54
  19. Steinmann E, Brohm C, Kallis S, et al. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J Virol. 2008;82:7034–7046
  20. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A. 2006;103:7408–7413
  21. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–640
  22. Hietakangas V, Poukkula M, Heiskanen KM, et al. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol. 2003;23:1278–1291
  23. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7:94–100
  24. Kayagaki N, Yamaguchi N, Nakayama M, et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med. 1999;189:1451–1460
  25. Ciesek S, Liermann H, Hadem J, et al. Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat. 2008;15:200–211
  26. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007;204:667–680
  27. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105:7034–7039
  28. Ahlenstiel G, Titerence RH, Koh C, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology. 2010;138:325–335
  29. Pilli M, Zerbini A, Penna A, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology. 2007;133:1132–1143
  30. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–163
  31. Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006;12:2640–2646
  32. Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology. 2007;46:1498–1508

 View this article's video abstract at www.gastrojournal.org.

 Conflicts of interest These authors disclose the following: Heiner Wedemeyer, Michael Manns, Markus Cornberg, and Johannes Wiegand have received lecturer fees and research funding from several companies involved in treating viral hepatitis C including Roche and Schering-Plough. The remaining authors disclose no conflicts.

 Funding This study was funded by the International Research Training Group 1273 funded by the German Research Foundation (DFG), the SFB center grant 738 (Project B2) funded by the DFG, a grant from the Bill and Melinda Gates Foundation through the Grand Challenges in Global Health Initiative (M.P.M. and H.W.), and the Bundesministerium für Bildung und Forschung grant 01Kl0788 (H.W. and M.C.).

 The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (accession number GSE15743, available: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15743).

PII: S0016-5085(10)00160-5

doi: 10.1053/j.gastro.2010.01.051

Gastroenterology
Volume 138, Issue 5 , Pages 1885-1897.e10 , May 2010

Article Tools

* Image Usage & Resolution